In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART-19) products for relapsed/refractory B cell lymphomas and leukemia. However, only ~30-40% of patients maintain a durable complete remission at long term.
In this webcast, Dr. Marco Ruella, an internationally recognized expert in cellular immunotherapies, will present research to improve CAR-T therapy for cancer by studying tumor evasion mechanisms and other limitations of CAR-T immunotherapy, and to rationally design novel approaches to overcome them.
Several interrelated factors contribute to the lack of response or relapse after CART-19, including tumor cell-intrinsic factors, CAR-T cell dysfunction, and an immunosuppressive tumor microenvironment (TME). This presentation will describe uses of a combination of next-generation techniques (scRNA sequencing, spatial transcriptomics, etc.) to characterize mechanisms of resistance, perform pre-clinical studies, and develop new CAR-T products.
You will learn:
• Mechanisms of resistance to CAR-T cells
• Next-generation techniques to study and develop novel CAR-T products
• Caveats on improving manual perturbation issues, highlighting rare sample management and the value of fit-for-purpose screening
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Curiox Biosystems, who retails sole responsibility for content. About this content.
Speaker
Marco Ruella, Scientific Director, Lymphoma Program, University of Pennsylvania
Marco Ruella, MD, focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapies with the goal of rationally designing combined innovative immunotherapies for relapsing/refractory leukemia and lymphoma. He is the author of numerous peer-reviewed publications on targeted immunotherapies for hematological cancers and is an inventor in several patents on CAR T therapy.
Moderator
Sarah Hiddleston, Nature Research Custom Media
Sarah Hiddleston is a freelance journalist who has worked with Nature Research Custom Media since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.
